Fundraising Fox

Biotech Startups

9,990 companies tagged Biotech, with their investors and founders.

Cardio Diagnostics Holdings

0 investors

Cardio Flow

CardioFlow develops medical devices for interventional cardiology, specifically addressing critical limb-threatening ischemia through non-surgical therapies. The company serves interventional cardiologists and cardiovascular specialists.

0 investors

CardioCell

0 investors

CardioWise

0 investors

CareDx

CareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.

0 investors

Carewave Medical

0 investors

Carewear

0 investors

Carmell Therapeutics

0 investors

Carmine Therapeutics

Carmine Therapeutics develops gene therapies using non-viral gene transfer vector systems based on extracellular vesicle technology. The company works on delivering genetic medicines and is affiliated with academic research from institutions including MIT and the National University of Singapore.

0 investors

Carna

0 investors

Carogen Corporaton

0 investors

Carolina Molecular

Carolina Molecular Instruments provides whole genome sequencing and genomic testing services for agricultural research, crop quality control, soil health assessment, and food safety applications. The company delivers strain-level pathogen identification and contamination detection for agricultural products and food science industries.

0 investors

Castle Creek Pharmaceuticals

0 investors

Catabasis Pharmaceuticals

0 investors

Cavion

0 investors

CBA Pharma

0 investors

CBC Biotechnologies

0 investors

CDI Laboratories

0 investors

Cearna

0 investors

Cebix

0 investors

Cedilla Therapeutics, Inc.

0 investors

CEL SCI

CEL-SCI Corporation is a biotech company developing immunotherapies, particularly Multikine, which is advancing through FDA regulatory processes. The company is focused on cancer treatment and has progressed to Phase 3 clinical trials.

0 investors

CeleCor Therapeutics

Celecor develops zalunfiban (Disaggpro), an investigational platelet inhibitor drug designed for rapid subcutaneous administration by first responders in pre-hospital treatment of STEMI heart attacks. The company focuses on acute cardiovascular care for patients experiencing the most severe form of heart attack.

0 investors

Celerpurus

0 investors

Other sectors & tags